Abstract
Aggressive treatment of CF lung disease has markedly increased survival of CF patients and intense research efforts over the last decades have led to new treatment strategies, many of which target the lower airways directly via aerosol. The addition of any new therapy not only needs to be assessed in view of its individual efficacy, but also in context with other established therapies. This review will summarize the current evidence on aerosol therapy in CF focussing on therapies that hydrate airways, mucolytic therapy with dornase alfa and inhaled antibiotics. The different therapeutic regimens will be critically assessed in context to address the question of whether these different drugs can be used interchangeably or should be used in combination in CF lung disease. Pediatr Pulmonol. 2008; 43:S3–S4. © 2008 Wiley-Liss, Inc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
